URGN
UroGen Pharma Ltd. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 20.29K | $750,361 | n/a | n/a |
| Q2 2026 | 76 | +11 | 16.33M | $600.16M | +14 | −3 |
| Q1 2026 | 68 | -2 | 16.64M | $299.41M | +7 | −9 |
| Q4 2025 | 71 | 0 | 16.74M | $392.08M | n/a | n/a |
| Q3 2025 | 18 | -2 | 12.72M | $253.85M | n/a | −2 |
| Q2 2025 | 17 | +1 | 7.27M | $99.60M | +1 | n/a |
| Q1 2025 | 13 | 0 | 4.33M | $47.90M | n/a | n/a |
| Q4 2024 | 13 | +2 | 6.43M | $68.46M | +2 | n/a |
| Q3 2024 | 10 | -2 | 7.92M | $100.53M | n/a | −2 |
| Q2 2024 | 12 | n/a | 7.91M | $132.72M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Adage Capital Partners ✦ | 3.30M | n/a | $55.37M | 0.1% | n/c | 1 | SEC ↗ |
| 2 | Point72 Asset Management ✦ | 2.45M | n/a | $41.10M | 0.1% | n/c | 1 | SEC ↗ |
| 3 | Millennium Management ✦ | 1.16M | n/a | $19.48M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 421.39K | n/a | $7.07M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 5 | Wellington Management ✦ | 156.08K | n/a | $2.62M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 6 | ARK Investment Management ✦ | 151.78K | n/a | $2.55M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Two Sigma Investments ✦ | 100.42K | n/a | $1.69M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 74.36K | n/a | $1.25M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 9 | Marshall Wace ✦ | 42.84K | n/a | $718,872 | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 10 | AQR Capital Management ✦ | 30.29K | n/a | $508,266 | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 11 | T. Rowe Price ✦ | 10.95K | n/a | $184,000 | 0.0% | n/c | 1 | SEC ↗ |
| 12 | D. E. Shaw & Co. ✦ | 10.84K | n/a | $181,946 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 171 holders, 46.40M shares, $801.72M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 2.20K sh · $80,791
Officer · 1.52K sh · $64,618
Officer · 871 sh · $37,383
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology